12th - 13th March, 2020

4th Annual MarketsandMarkets Next Gen Immuno-Oncology Congress

ILEC Conference Center and IBIS London Earls Court, 47 Lillie Road, London, SW6 1UD

In the past decade, many scientific breakthroughs have been achieved through research including success in recent years of cancer immunotherapy with monoclonal antibodies, cancer vaccines, adoptive cell therapy and immune-checkpoint therapy. Personalized immunotherapy with various combinations will be the next promising strategy for the future cancer treatment direction.

  • 30+ experts from academia and industry will be presenting their current work in Immuno-Oncology, Latest updates on regulatory guidelines and approvals, Validation markers for tumor-derived T-cell subpopulations, NextGen T-Cell and CAR-T Cell therapy, Personalized Medicine, Biomarkers and Cancer Immunotherapy
  • Opportunity to develop long-lasting business relationships and networking opportunities with researchers, scientists, clinicians, academicians and professionals from Pharmaceutical companies, Bio-pharma companies, Universities, and Research institutes.
  • Over 20 presentations, round-tables, and panel discussions focused on the key opportunities and challenges in biomarker research, Validation methods and innovative tools in IO Discovery, Oral T-Cell Therapies for the Treatment of Cancer Patients and Discovery of novel bispecific antibody molecules to boost anti-tumor immunity

Our 4th Annual MarketsandMarkets Next Gen Immuno-Oncology Congress to be held on 12th-13th Macrh 2020 in London, UK would address the challenges and future directions in IO research. The congress aims to bring academicians, researchers and scientists from research institutes pharmaceutical, bio-pharmaceutical and biotechnology companies to discuss the latest updates in development of ADC’s, Bispecific Antibodies, Cellular Therapy and Immune Checkpoint Inhibitors. This congress would also focus on various combination strategies, pre-clinical and translational immune-oncology developments, updates in cellular and viral therapies, vaccines development and personalized immunotherapy. Keynote presentations, Brainstorming Panel Discussions and Case studies will give the stakeholders an opportunity to discuss and understand the issues faced and come up with solutions.

CONFERENCE SPEAKERS

Advisors
Stefan Gluck
Stefan Gluck
Vice President
Celgene, USA
Eugene Zhukovsky
Eugene Zhukovsky
Chief Scientific Officer
Biomunex Pharmaceuticals, France
Sophia Karagiannis
Sophia Karagiannis
Professor, Translational Cancer Immunology and Immunotherapy
King’s College London, UK
Speakers
Roy Baynes
Roy Baynes
Senior Vice President and Head, Global Clinical Development, Chief Medical Officer
Merck Sharp & Dohme, USA
Shailendra Singh (Shelly)
Shailendra Singh (Shelly)
Chief Operating Officer
MarketsandMarkets
Steven F. Schellings
Steven F. Schellings
Associate Director, Cellular Therapy, Account Management
Novartis, USA
David Gilham
David Gilham
Vice President, R&D
Celyad, UK
Danny Wells
Danny Wells
Principal Investigator
Parker Institute for Cancer Immunotherapy, USA
Bruno Tullia
Bruno Tullia
Assistant Professor
UPMC Hillman Cancer Center, USA
Scott Durum
Scott Durum
Head, Cytokines and Immunity
NIH
Debiprasad Roy
Debiprasad Roy
Senior Director, R&D Technology Platforms
Allogene Therapeutics, USA
Soldano Ferrone
Soldano Ferrone
Professor of Surgery
Harvard University, USA
John Maher
John Maher
Chief Scientific Officer
Leucid Bio, UK
Junjian Liu
Junjian Liu
Vice President, Biologics Discovery
Innovent Biologics, China
Sebastien Tabruyn
Sebastien Tabruyn
CSO
TransCure bioServices SAS, France
Stefan Gluck
Stefan Gluck
Vice President
Celgene, USA
Eugene Zhukovsky
Eugene Zhukovsky
Chief Scientific Officer
Biomunex Pharmaceuticals, France
Andrew Sewell
Andrew Sewell
Professor, Division of Infection and Immunity
Cardiff University, UK
Ann White
Ann White
Senior Principal Scientist
UCB Celltech, UK
Sophia Karagiannis
Sophia Karagiannis
Professor, Translational Cancer Immunology and Immunotherapy
King’s College London, UK

SPONSORS

LOCATION

ILEC Conference Center and IBIS London Earls Court, 47 Lillie Road, London, SW6 1UD
About the Hotel

A west London gem, The venue is known to the expert planner for the formidable flexibility and large capacity. The sleek design of the main hall, the London Suite, is positively favored for its ingenious partitioning and dazzling night-ambiance. Thus whether you are looking for an exhibition space, a meeting, an award ceremony, a corporate summer or Christmas party or a conference venue in London, our award-winning team will be certain to deliver the event you need and want.